Deeper Knowledge, Faster

  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Cantor Fitzgerald
Argus Health
Daiichi Sankyo
US Army
Chinese Patent Office

Generated: November 22, 2017

DrugPatentWatch Database Preview

Details for Patent: 5,914,122

« Back to Dashboard

Summary for Patent: 5,914,122

Title: Stable budesonide solutions, method of preparing them and use of these solutions as enema preparations and pharmaceutical foams
Abstract:A stable budesonide solution with a pH not exceeding 6.0 in which the budesonide is dissolved in a solvent which may be water, an alcohol such as ethanol, isopropanol or propylene glycol, or a water/alcohol mixture. The solution preferably also contains a stabilizer such as sodium ethylenediaminetetraacetic acid, cyclodextrins or mixtures thereof. The stable budesonide solution is useful as the active ingredient in a rectal enema or a rectal foam.
Inventor(s): Otterbeck; Norbert (Uberlingen, DE), Kuhn; Reimund (Freiamt, DE)
Assignee: Dr. Falk Pharma GmbH (Freiburg, DE)
Application Number:08/860,136
Patent Claim Types:
see list of patent claims
Formulation; Process;

No matches for this query

Foreign Priority and PCT Information for Patent: 5,914,122

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Germany44 46 891Dec 27, 1994

International Patent Family for Patent: 5,914,122

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Canada2205305► Subscribe
Denmark0794767► Subscribe
Germany59502928► Subscribe
Germany4446891► Subscribe
European Patent Office0794767► Subscribe
Austria168556► Subscribe
Spain2120247► Subscribe
Greece3027632► Subscribe
JapanH10511364► Subscribe
Japan3421348► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Chinese Patent Office
Cantor Fitzgerald
Federal Trade Commission
US Department of Justice

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

Google Plus